Monovaccines refers to vaccines that provide protection against a single pathogen or disease. EBV monovaccine helps in preventing infectious mononucleosis caused by the Epstein–Barr virus. It offers advantages like conferring lifelong immunity, protection from various cancers associated with EBV infection and reducing disease burden in resource limited countries.
Market key trends:
One of the major trends in the monovaccine market is rising investment by manufacturers in research and development of EBV vaccines. As per statistics, around 95% of adult population gets infected by EBV at some point in their life making it an attractive target pathogen for vaccination development. Further, increasing awareness about EBV linked cancers like Burkitt's lymphoma and nasopharyngeal carcinoma is also driving the demand for preventive EBV vaccines. Regulatory approvals and successful clinical trials of few EBV vaccine candidates indicates the market is moving steadily towards the availability of first licensed EBV immunization in the coming years.
Segment Analysis
The monovaccine market for Epstein - Barr virus (EBV) is currently dominated by the preventive vaccine segment. This segment held around 70% of the total market share in 2023 due to the increasing focus on preventing infectious mononucleosis caused by EBV. EBV commonly infects adolescents and young adults. Preventive EBV monovaccines help reduce the risk of developing infectious mononucleosis and certain associated complications.
Key Takeaways
The global Monovaccine Market Analysis for Epstein - Barr virus is expected to witness high growth, exhibiting a CAGR of 5.3% over the forecast period, due to increasing healthcare spending and disease awareness.
Regional analysis
North America currently dominates the global EBV monovaccine market,owing to advanced healthcare infrastructure and high adoption of viral infection vaccines in the region. Asia Pacific is expected to be the fastest-growing market during the forecast period due to the increasing awareness about infectious diseases, growing healthcare expenditure, and rising focus of market players in this region.
Key players
Key players operating in the monovaccine market for Epstein - Barr virus are Pfizer Inc., GlaxoSmithKline, Biomed Pvt. Ltd., Serum Institute of India, Baxter International, Sanofi S.A., Neuro Biotech, Merck, JN-International, and CNGB. Pfizer Inc. and GlaxoSmithKline are the dominating players due to their extensive geographical presence and wide EBV vaccine portfolio.
The global monovaccine market for Epstein - Barr virus is expected to witness high growth, exhibiting a CAGR of 5.3% over the forecast period, due to increasing healthcare spending and rising disease awareness. The market size is expected to reach US$ 13.78 billion by 2030 from US$ 10.42 billion in 2023.
Get more insights on this topic: https://www.newsstatix.com/monovaccine-epstein-barr-virus-market-size-share-outlook-and-opportunity-analysis-2018-2026/
Comments
0 comment